In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Insmed (INSM – Research Report), with a price target of $98.00.
In a note early Tuesday, TD Cowen analyst Ritu Baral said that the outcome of the brensocatib trial at both dosage levels was ...
TD Cowen analyst Ritu Baral reiterated a Buy rating on Vera Therapeutics (VERA – Research Report) yesterday and set a price target of $60.00. The company’s shares closed last Friday at $27.46.
Distributor relationships are being explored in the Middle East and North Africa. Ritu Baral, Analyst, TD Cowen: We’re going to go ahead and get started. Thank you very much for joining us for ...